1 / 15

A-MOP: An Antipsychotic Medication Optimization Program for Long Term Care

A-MOP: An Antipsychotic Medication Optimization Program for Long Term Care. Fiona Sudbury, RN, Director of Care Duncan Robertson , Chief of Medical Staff The Lodge at Broadmead Victoria, B.C., Canada. The Lodge at Broadmead. Population served. Many Veterans 65% male

montana
Download Presentation

A-MOP: An Antipsychotic Medication Optimization Program for Long Term Care

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. A-MOP: An Antipsychotic Medication Optimization Program for Long Term Care Fiona Sudbury, RN, Director of Care Duncan Robertson , Chief of Medical Staff The Lodge at Broadmead Victoria, B.C., Canada

  2. The Lodge at Broadmead

  3. Population served Many Veterans 65% male Average age 88 50% admitted from hospital ALOS ~ 18 mos ~80% mod - severe dementia

  4. Medication Optimization Program • Admission & regular review of medication • Beer’s list audits • Staff education and good practice guidelines • Policy development

  5. Antipsychotic Concerns!

  6. A-MOP Project Framework • Baseline descriptive statistics • Audit and clinical review • Make recommendations to prescriber • Develop new policy and procedure for antipsychotic drug use • Staff education and support • Ongoing quality monitoring

  7. Atypical AntipsychoticUse - June 2011 – Time 1

  8. Average Daily Dose

  9. Audit Form & Clinical Review • RN audit: diagnosis, drug, dosage and frequency • Reason for use - behaviour of concern • Non-pharmacological strategies in care plan • Antipsychotic medication history • 3 month’s documentation of behaviour of concern • Review with Medical Coordinator or Geriatric Psychiatrist • Recommendation to primary care physician

  10. Results - Time 1 Audits (N=62) • Indication for use: • 73% - Dementia (AD, VaD, Mixed) • 27% - Other psychiatric diagnoses • Rationale documented for 83% of residents • Most common reason - aggression and/or risk to self or others • Care plan review • 57% had non-pharmacological strategies identified • Medication history • 50% started lower than current dose

  11. Impact of Recommendations to Physicians • 14 residents - drug discontinued • Of these, 7 prescribed PRN dose • 9 residents - dose reduced • 4 residents – no change advised • 3 residents - dose increased advised • 6 residents died before review completed

  12. Comparison of Atypical Antipsychotic Use: T1 - T2

  13. Project Successes • Clearer picture of atypical antipsychotic drug use in this care home • Increased team awareness of the risks and good practice principles for use of atypical antipsychotics • Pride in our apparently lower use than other care homes in our region

  14. New Policy & Procedure • Prior to initiation: • Behaviour assessment • Treat causes of BPSD i.e. Pain, infection, depression • Care plan non-pharmacological interventions • On initiation: • Clear identification of behaviour of concern • Information and consent with family • Lowest effective dose • Ongoing monitoring: • Monitoring for effect and adverse effects • Review every 3 months • If no behaviour of concern, trial of dose reduction/withdrawal • Auto stop for PRN antipsychotics not used in 3 months • Quality monitoring of antipsychotic use Q 6 months

  15. Final thoughts

More Related